Outcomes of pharmacological and surgical treatment for obesity

PharmacoEconomics

Volumn 14, Issue 3, 1998, Pages 269-283

  Cerulli, Jennifer ^a   Malone, Margaret ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; ANTIOBESITY AGENT; DEXFENFLURAMINE; FENFLURAMINE; MAZINDOL; METHAMPHETAMINE; PHENMETRAZINE; PHENTERMINE; SEROTONIN 1A RECEPTOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

APPETITE; BODY MASS; CHRONIC DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ECONOMIC EVALUATION; HUMAN; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SURGICAL APPROACH;

HUMANS; OBESITY; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0031712986     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814030-00004     Document Type: Review

References (59)

1. Williamson DF. Descriptive epidemiology of body weight and weight change in U.S. adults. Ann Intern Med 1993; 119 (7 Pt 2): 646-9
2. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes 1998; 22: 39-47
3. Bray GA. Pathophysiology of obesity. Am J Clin Nutr 1992; 55 Suppl.: 488S-94S
4. Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med 1997; 337 (6): 398-407
5. McGinnis M, Foege WH. Actual causes of death in the United States. JAMA 1993; 270 (18): 2207-12
6. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995; 333 (11): 677-85
7. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993; 119 (7 t 2): 655-60
8. Wolf AM, Colditz GA. Social and economic effects of body weight in the United States. Am J Clin Nutr 1996; 63 Suppl.; 466S-9S
9. Fontaine KR, Cheskin LJ, Barofsky I. Health-related quality of life in obese persons seeking treatment. J Fam Pract 1996; 43 (3): 265-70
10. Lean MEJ, Han TS, Seidell JC. Impairment of health and quality of life in people with large waist circumference. Lancet 1998; 351: 853-6
11. Wolf AM, Colditz GA. The cost of obesity: the US perspective. Pharmacoeconomics 1994; 5 Suppl. 1: 34-7
12. Sjöström L, Narbro K, Sjöström D. Costs and benefits when treating obesity. Int J Obes 1995; 19 Suppl. 6: 9S-12S
13. Seidell JC. The impact of obesity on health status: some implications for health care costs. Int J Obes 1995; 19 Suppl. 6: 13S-6S
14. Quesenberry CP, Caan B, Jacobson A. Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med 1998; 158: 466-72
15. Gorsky RD, Shaffer PA, Pamuk E, et al. The 25-year health care costs of women who remain overweight after 40 years of age. Am J Prev Med 1996; 12 (5): 388-94
16. National Task Force on the Prevention and Treatment of Obesily. Long-term pharmacotherapy in the management of obesity. JAMA 1996; 276 (23): 1907-15
17. National Institutes of Health (NIH). Gastrointestinal surgery for severe obesity. Ann Intern Med 1991; 9 (1): 25-7
18. Williamson DF, Pamuk E, Thun M, et al. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol 1995; 141 (12): 1128-41
19. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes 1992; 16: 1-19
20. Stunkard AJ. Current views on obesity. Am J Med 1996; 100: 230-6
21. Bray GA. The new era of drug treatment. Pharmacologic treatment of obesity: symposium overview. Obes Res 1995; 3 Suppl. 4: 415S-7S
22. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993; 119 (7 Pt 2): 707-13
23. Dahms WT, Molitch ME, Bray GA, et al. Treatment of obesity: cost-benefit assessment of behavioral therapy, placebo, and two anorectic agents. Am J Clin Nutr 1978; 31: 774-8
24. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337 (9): 581-8
25. Centers for Disease Control. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997; 46 (45): 1061-6
26. The International Primary Pulmonary Hypertension Study (IPPHS). Chest 1994; 105 Suppl. 2: 37S-41S
27. Abenhaim L, Moride Y, Brenot F, et al. Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335 (9): 609-16
28. Manson JE, Faich GA. Pharmacotherapy for obesity: do the benefits outweigh the risks? N Engl J Med 1996; 335 (9): 659-60
29. Weintraub M, Sundaresan PR, Madan M, et al. Long-term weight control study 1 (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 1992; 51 (5): 586-94
30. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study II (weeks 34 to 104): an open label study of continuous fenfluramine plus phentermine versus targeted intermittent medications as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther 1992; 51 (5): 595-601
31. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study III (weeks 104 to 156): an open-label study of dose adjustment of fenfluramine and phentermine. Clin Pharmacol Ther 1992; 51 (5): 602-7
32. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study IV (weeks 156-190): the second double-blind phase. Clin Pharmacol Ther 1992; 51 (5): 608-14
33. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study V (weeks 190-210): follow-up of participants after cessation of medication. Clin Pharmacol Ther 1992; 51 (5): 615-8
34. Weintraub M, Sundaresan PR, Cox C. Long-term weight control study VI: individual participant response patterns. Clin Pharmacol Ther 1992; 51 (5): 619-33
35. Weintraub M, Sundaresan PR, Schuster B. Long-term weight control study VII (weeks 0 to 210): serum lipid changes. Clin Pharmacol Ther 1992; 51: 634-41
36. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther 1992; 51 (5): 642-6
37. Guy-Grand B, Apfelbaum M, Crepaldi G, et al. International trial of long-term dexfenfluramine in obesity. Lancet 1989; 2: 1142-4
38. McTavish D, Heel RC. Dexfenfluramine. Drugs 1992; 43 (5): 713-33
39. Davis R, Faulds D. Dexfenfluramine: an updated review of the therapeutic use in the management of obesity. Drugs 1996; 32 (5): 696-724
40. Guy-Grand B. Clinical studies with dexfenfluramine: from past to future. Obes Res 1995; 3 Suppl. 4: 491S-6S
41. Scheen AJ, Paolisso G, Salvatore T, et al. Improvement of insulin-induced glucose disposal in obese patients with NIDDM alter 1 week treatment with d-fenfluramine. Diabetes Care 1991; 14 (11): 325-32
42. Willey KA, Molyneaux LM, Overland JE, et al. The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. Diabet Med 1992; 9: 341-3
43. Stewart GO, Stein GR, Davis TME, et al. Dexfenfluramine in type II diabetes: effect on weight and diabetes control. Med J Aust 1993; 158: 167-9
44. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes 1997; 21 Suppl. 1:25S-9S
45. Lean MEJ. Sibutramine: a review of clinical efficacy. Int J Obes 1997; 21 Suppl. 1: 30S-9S
46. Bray GA, Ryan DH, Gordon D, et al. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996; 4 (3): 263-70
47. Weintraub M, Rubio A, Golik A, et al. Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther 1991; 50 (3): 330-7
48. Ryan DH, Bray GA, Wilson JK, et al. Treatment for 21/2 years with sibutramine [abstract]. Obes Res 1996; 4 Suppl. 1: 31S
49. Guerciolini R. Mode of action of orlistat. Int J Obes 1997; 21 Suppl. 3: 12S-23S
50. Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes 1993; 17: 241-4
51. Drent ML, Larsson I, William-Olsson T, et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes 1995; 19: 221-6
52. James WPT, Avenell A, Broom J, et al. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes 1997; 21 Suppl. 3: 24S-30S
53. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes. Ann Surg 1995; 222 (3): 339-52
54. MacDonald KG, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality on non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997; 1: 213-20
55. Karlsson J, Sjostrom L, Sullivan M. Swedish obese subjects (SOS): an intervention study of obesity. Two-year follow-up of health-related quality of life (HRQL) and eating behavior after gastric surgery for severe obesity. Int J Obes 1998; 22 (2): 113-26
56. van Gemert WG, Adang EM, Greve JWM, et al. Quality of life assessment of morbidly obese patients: effect of weight-reducing surgery. Am J Clin Nutr 1998; 67: 197-201
57. Isacsson Å, Frederiksen SG, Nilsson P, et al. Quality of life after gastroplasty is normal: a controlled study. Eur J Surg 1997; 163: 181-6
58. Mason EE, Renquist KE, Jiang D. Perioperative risks and safety of surgery for severe obesity. Am J Clin Nutr 1992; 55 Suppl.: 573S-6S
59. Martin LF, Tjiauw-Ling T, Horn JR, et al. Comparison of the costs associated with medical and surgical treatment of obesity. Surgery 1995; 118 (4): 599-607